51.1 F
New York
Monday, November 28, 2022

Date:

Share:

Personalized Immune Therapy Shown to Extend Survival in Patients with Aggressive Brain Cancer

Related Articles

ClinicalPURSUIT Offers Free Demonstration to Help Clinical Research Understand Their System and How It Can Help During Clinical Trials

Clayton, MO, November 25, 2022 --(PR.com)-- Clinical trials are expensive to conduct but are also essential in modern medicinal and therapeutic development. There is a...

ClinicalPURSUIT’s Software Offers Interactive Randomization Technology and RTSM to Help Researchers Conduct Flawless Clinical Research

Clayton, MO, November 25, 2022 --(PR.com)-- Clinical trials are crucial to developing modern medicines and therapeutic treatments. These research and trials are expected to be...

ClinicalPURSUIT’s Configurable Dashboards Assists Researchers in Conducting Clinical Research

Clayton, MO, November 25, 2022 --(PR.com)-- Clinical trials are fundamental to the success of modern medicinal and therapeutic development. However, there is a great need...
Denver, CO, November 22, 2022 –(PR.com)– A Phase III clinical trial of the DCVax®-L cancer vaccine, conducted at the Sarah Cannon Research Institute at HealthONE and other centers internationally, has shown that the vaccine extended median survival and also the “long tail” of extended survival in both newly diagnosed and recurrent glioblastoma brain cancer. The trial results were reported today in a publication co-authored by Michael Pearlman, MD from the Sarah Cannon Research Institute in the prestigious cancer journal JAMA Oncology.

This is the first time in nearly 20 years that a Phase III trial of a systemic treatment has shown such survival extension in newly diagnosed glioblastoma, and the first time in nearly 30 years that a Phase III trial of any type of treatment has shown such survival extension in recurrent glioblastoma.

“We are truly excited to see the meaningful survival extensions glioblastoma patients treated…

Read more…

Popular Articles